Biohaven has concluded enrolment of 180 patients in a Phase III study evaluating taldefgrobep alfa as adjunctive therapy in patients with spinal muscular atrophy (SMA).

The pivotal, placebo-controlled, double-blind study is being carried out in nine countries.

The key goal of the trial is to establish the efficacy and safety of the myostatin inhibitor taldefgrobep alfa.

These parameters are determined by change from baseline in the 32 item Motor Function Measure (MFM-32) total score.

Patients who previously received treatments with either nusinersen, risdiplam, and onasemnogene abeparvovec-xioi are included in the study.

They will receive taldefgrobep alfa or placebo subcutaneously for 48 weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biohaven vice-president and SMA programme clinical development lead Lindsey Lair said: “Despite recent advances in SMA genetic treatments, patients still experience weakness and impairments in quality of life that can be alleviated by enhancing muscle mass and function, on top of what is delivered by current standard of care treatments.

“Our team has been inspired by the entire global SMA community of clinicians, patients and family members – we are particularly grateful to the patients and investigators who helped us complete enrolment ahead of our timelines.”

Taldefgrobep received both fast track and orphan drug designation from the US Food and Drug Administration and orphan drug designation from the European Union.

Taldefgrobep is a muscle-targeted recombinant protein targeting two key regulators of muscle mass and adipose tissue including myostatin and activin A signalling.

In combination with other therapies that increase SMN protein levels in the body, taldefgrobep alfa enhances muscle mass in SMA patients and further improves motor function.